Plasmablastic lymphoma(PBL) shows a low incidence and poor prognosis, moreover, there is no standard treatment regimen for PBL. The treatment effect and value of CHOP regimen and radiotherapy are limited. Some studies showed that intensive chemotherapy alone or its combination with proteasome inhibitors or immune regulator can improve the overall survival of patients with PBL, which can be used as the first-line therapy for PBL patients. CAR-T and immunocheckpoint inhibitors showed treatment effect for the patients with refractory and relapsed plasmablastic lymphoma. The clinical value of potential targets in treating tumour worth to be studied further.
题目: 浆母细胞性淋巴瘤治疗的最新研究进展.
摘要: 浆母细胞性淋巴瘤（plasmablastic lymphoma，PBL) 发病率低、预后差，且目前无标准的治疗方案。传统CHOP方案治疗效果不佳，放射治疗的价值有限。有相关研究表明，采用高强度化疗方案，联合或不联合蛋白酶体抑制剂、免疫调节剂，能改善PBL患者的生存，可作为PBL患者的一线治疗选择。CAR-T及免疫检查点抑制剂在复发难治PBL患者中显示出一定的治疗效果，这有望成为治疗方向。潜在治疗靶点临床价值有待进一步研究.